New Pancreatic Cancer Treatment Doubles Survival Rates in Clinical Trials
Updated
Updated · New Hampshire Business Review · Aug 4
New Pancreatic Cancer Treatment Doubles Survival Rates in Clinical Trials
3 articles · Updated · New Hampshire Business Review · Aug 4
Summary
Clinical trial data presented at last month’s cancer conference showed a new pancreatic cancer treatment doubled average survival rates, a rare advance for a disease usually detected late.
Years of research, rigorous testing and sustained scientific investment produced the result, according to the letter, which framed the therapy as evidence of how long-horizon drug development can pay off.
School nurses said the breakthrough gives families new hope while reinforcing the need for healthcare policies that preserve both treatment affordability and incentives for future pharmaceutical research.